Clinical Trial Goal
To find out if glofitamab, in combination with standard treatment, is safe and works well to treat DLBCL, HGBCL or transformed lymphoma in older or weak adults
You may be able to join this trial if you:
- Are 65 to 80 years old
- Have one of the following, and have had little to no treatment:
- DLBCL
- HGBCL
- Transformed lymphoma
- Do not have lymphoma in your brain or spinal cord
- Have not been treated with a monoclonal antibody. Your doctor can tell you this
- Have not had allogeneic (cells from a donor) blood or marrow transplant (BMT)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Cyclophosphamide and doxorubicin are chemotherapy (chemo) drugs that block the growth of cancer cells.
Glofitamab is a bispecific monoclonal antibody that targets CD 3 and CD20 on certain cells.
Obinutuzumab is a monoclonal antibody that targets CD20 on certain cells.
Polatuzumab is a monoclonal antibody-drug conjugate, or combination, that targets CD79b on certain cells.
Rituximab is a monoclonal antibody that targets CD20 on certain cells.
You’ll get:
Glofitamab is a bispecific monoclonal antibody that targets CD 3 and CD20 on certain cells.
Obinutuzumab is a monoclonal antibody that targets CD20 on certain cells.
Polatuzumab is a monoclonal antibody-drug conjugate, or combination, that targets CD79b on certain cells.
Rituximab is a monoclonal antibody that targets CD20 on certain cells.
You’ll get:
- Cyclophosphamide – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
- Doxorubicin – Given as IV infusions. The dose you'll get depends on when you start the trial and how safe it has been
- Glofitamab – Given as IV infusions. The dose you'll get depends on when you start the trial and how safe it has been
- Obinutuzumab - Given as IV infusions. The dose you'll get depends on when you start the trial and how safe it has been
- Polatuzumab - Given as IV infusions. The dose you'll get depends on when you start the trial and how safe it has been
- Rituximab - Given as IV infusions. The dose you'll get depends on when you start the trial and how safe it has been
You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 1 year.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them in this combination to treat DLBCL, HGBCL or transformed lymphoma in older or weak adults is new and unproven.
Locations
Sponsors
collaborator: Genentech, Inc., lead: Memorial Sloan Kettering Cancer Center
